Board of Directors
Julie Cherrington - Non Executive Director
Jim Hazel, BEc, FFin, FAICD - Non Executive Director, Chairman elect
Mr Hazel, has had an extensive career in banking and investment banking, including as chief general manager of Adelaide Bank Ltd. Until recently he was managing director of an ASX listed retirement village and aged care operation. He is Chairman of Elders Rural Bank Limited, a director of Becton Property Group Limited, Terramin Australia Limited and Impedimed Limited. He is also Chairman of Valex Group Pty Ltd and a board member of the Council on the Aging (SA) Inc. He has previously been a director of the South Australian Government
Financing Authority, Tourism SA, Peptech Limited and St Andrews
Hospital Inc.
Cherrell Hirst, MBBS, BEdSt D, Univ (Hon)
FAIM, FAICD - Non
Executive Director
Dr
Hirst started out in clinical medicine and she was assistant Director
and then Director of the Wesley Breast
Clinic for almost 20 years. Dr Hirst is Deputy Chair of life sciences
venture capital fund Queensland
BioCapital Funds (QBF) a non
executive director of Peplin Inc. and Impedimed Ltd. She served as a
member of the AusIndustry IR&D Board Biological
Committee from 2001-6. Dr Hirst holds directorships in financial
services companies including Suncorp and MBF. Dr Hirst was Chancellor
of QUT from 1994-2004 and has received three honorary doctorates, the
award of Officer of the Order of
Australia and a centenary medal in recognition of her work in breast
cancer and education. Dr Hirst was Queenslander of
the Year in 1995.
Andrew Baker, BSc PhD - Non Executive Director
Dr Baker has over
18 years experience in the pharmaceutical and biotechnology industries,
including 14 years working with industry leaders Genentech, Bayer and
Johnson & Johnson where he had
key responsibilities in directing pharmaceutical and
biotechnology research, and identifying and evaluating technology
opportunities. Before joining GBS in 2002, he was Deputy Director of Johnson
& Johnson Research in Sydney.
Julie Cherrington, PhD - Non Executive Director
Dr Cherrington is CEO, Pathway Therapeutics, and joined the Xenome Board as an independent, Non-Executive Director on 1 August 2009. She has held numerous posts in Australia and the United States in biotechnology companies, including seats on the boards of ChemGenex and Progen Pharmaceuticals, and senior research positions at prominent biotechnology companies such as SUGEN, Inc and Gilead Sciences, Inc.
Michael Aldridge, BSc (Hons), MAppFin - Executive Director
Mr Aldridge joined Xenome as Executive Director in March 2010. He has an extensive background in the global
biotechnology and pharmaceutical industries having held leadership,
strategic, consulting and financing roles in North American, European
and Australian companies. As CEO, Board Director and Consultant with Peplin, Inc. from October 2003, Michael led the growth of a global, dermatology focused, product
company developing a new approach to the treatment of skin cancer.
Peplin was sold to LEO Pharma A/S, a European dermatology company, for
US$287.5 million in cash in September 2009. From September 2002 to September 2003, Mr. Aldridge served as a Director of Wilson HTM, an investment bank, in Brisbane, Australia. From 2000 to 2002, he served as an Associate Director of Bear, Stearns & Co.’s Healthcare Investment Banking Group. Prior to that, Mr. Aldridge held similar positions with Volpe Brown Whelan & Company in San Francisco and with the SG Warburg Group in Sydney and London. Mr. Aldridge received a B.S. in chemistry with honors from the University of Canterbury, New Zealand and an M.A. in applied finance from Macquarie University, Sydney, Australia.
|
